Bladder News and Research

RSS

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.

1 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010

Saving soldier's life takes precedence over treating traumatic urologic injury on battlefield

Saving a soldier's life takes precedence over treating traumatic urologic injuries on the battlefield, a Medical College of Georgia researcher says.

30 Oct 2010

NeoGenomics third quarter revenue grows 19% to $8.7 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2010.

28 Oct 2010

NICE issues PTNS guidance for overactive bladder

Uroplasty, Inc. announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued a guidance document titled "Percutaneous Posterior Tibial Nerve Stimulation for Overactive Bladder Syndrome," reinforcing the safety and effectiveness of PTNS for overactive bladder.

28 Oct 2010

Annals of Urology to publish NAFC research on overactive bladder symptoms

Research by the National Association For Continence (NAFC) about the frustration endured by middle-aged women, who have overactive bladder (OAB) symptoms, will be published in the inaugural issue of Annals of Urology from San Lucas Medical.

28 Oct 2010

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

A new British review of existing research suggests that while a newer type of radiation for the treatment of prostate cancer does not help patients live longer compared to an older type at least when similar doses are given it does appear to reduce gastrointestinal side effects.

27 Oct 2010

IMRT reduces gastrointestinal complications in prostate cancer patients

Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Chemoradiotherapy can reduce bladder cancer recurrence

A major bladder cancer trial, funded by Cancer Research UK, has shown that adding two commonly used chemotherapy drugs to traditional radiotherapy can reduce the chance of a patient's tumour coming back by a third.

26 Oct 2010

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Combination of chemotherapy and radiation improves control of cancer within bladder

Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Tengion, Inc., a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit™ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal.

25 Oct 2010

OncoGenex completes public offering of 3,174,602 units

OncoGenex Pharmaceuticals, Inc. today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit for an aggregate offering amount of $50 million, as previously announced on October 18, 2010.

25 Oct 2010

Salix acquires rights to colon cancer screening agent from Photocure

Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.

20 Oct 2010

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting in San Diego seems to confirm that a single, small dose of the steroid dexamethasone improves the post-surgical quality of life of patients receiving laparoscopic gallbladder surgery.

20 Oct 2010

BCAN holds regional Bladder Cancer Patient Forum at New York Academy of Medicine

Bladder cancer is the fifth most commonly diagnosed cancer in the United States, yet most people know nothing about it. To help enhance the public's understanding of the risks and signs of bladder cancer and the importance of early detection and treatment options, the Bladder Cancer Advocacy Network (BCAN) will hold its regional Bladder Cancer Patient Forum "Understanding Bladder Cancer" on Saturday, October 23, 2010, in New York City at the New York Academy of Medicine.

20 Oct 2010

Bladder News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Allergan third quarter diluted loss per share increases to $2.21

Saving soldier's life takes precedence over treating traumatic urologic injury on battlefield

NeoGenomics third quarter revenue grows 19% to $8.7 million

NICE issues PTNS guidance for overactive bladder

Annals of Urology to publish NAFC research on overactive bladder symptoms

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

IMRT reduces gastrointestinal complications in prostate cancer patients

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Chemoradiotherapy can reduce bladder cancer recurrence

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Combination of chemotherapy and radiation improves control of cancer within bladder

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

OncoGenex completes public offering of 3,174,602 units

Salix acquires rights to colon cancer screening agent from Photocure

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

BCAN holds regional Bladder Cancer Patient Forum at New York Academy of Medicine

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News